Jim McNally, Ph.D.
Chief Scientific Officer
Jim McNally, Ph.D., Chief Scientific Officer, has an extensive background in bioanalytical assay development and program leadership spanning more than 20 years working in the pharmaceutical and biotechnology industry. Prior to joining BioAgilytix, Dr. McNally was Executive Director at CRISPR Therapeutics, where he led a team of scientists to develop a portfolio of assays to support development of gene-based therapeutic candidates throughout their lifecycle. He has also previously held roles at Genzyme, Pfizer, EMD Serono, and Shire/Takeda which have given him broad experience in the development of large molecule, gene therapy, and cell therapy biotherapeutics. He has a special interest in the immunogenicity of biotherapeutics and leads an industry-wide working group to address this issue. A key part of his role at BioAgilytix is advising on emerging scientific developments and providing scientific and regulatory guidance. Dr. McNally obtained his B.S. in Biology from Mississippi State University, his Ph.D. in Viral Immunology from Louisiana State University School of Medicine in Shreveport, and a Post-Doctoral fellowship in Viral Immunology at University of Massachusetts Medical School.
